

Date: May 19, 2023

To, **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Scrip Code: 543434

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai - 400 051 Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Intimation of Board Meeting under Regulation 29(1) of SEBI (Listing Obligations and **Disclosure Requirements) Regulations, 2015**

In terms of Regulation 29 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Friday, May 26, 2023, inter alia to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2023 and to recommend dividend, if any, for the financial year ended March 31, 2023.

This is further to inform you that with reference to our letter dated March 30, 2023 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Audited Financial Results for the quarter and year ended March 31, 2023.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully, For Supriya Lifescience Limited

Shweta Singh **Company Secretary & Compliance Officer** Membership No.: A44973

Corporate office	: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
	Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A12X
	CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com
Factory	: A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.